---
title: "Akari Therapeutics Plc 1Q 2026: Net income $(14.5M), EPS $(0.00) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286968149.md"
description: "Akari Therapeutics Plc reported a net loss of $(14.5M) in Q1 2026, widening from $(3.7M) in Q1 2025, with no product sales as the company remains pre-revenue. Diluted EPS was $(0.00) for both quarters. The company initiated GMP manufacturing for AKTX-101 and is focusing on its PH1-based ADC platform. An ASCO 2026 abstract was accepted for research on KRAS-mutated pancreatic cancer."
datetime: "2026-05-19T21:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286968149.md)
  - [en](https://longbridge.com/en/news/286968149.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286968149.md)
---

# Akari Therapeutics Plc 1Q 2026: Net income $(14.5M), EPS $(0.00) — 10-Q Summary

Akari Therapeutics Plc reported a widened net loss in the first quarter of 2026, posting a $(14.5M) net loss and diluted loss per share of $(0.00) as the company remains pre-revenue with no product sales recorded for the quarter.

**Financial Highlights**

-   Net income: $(14.5M) net loss for Q1 2026, compared with $(3.7M) net loss in Q1 2025 (widened loss YoY).
-   Diluted earnings per share: $(0.00) for Q1 2026, compared with $(0.00) for Q1 2025.
-   Revenue: Not reported for Q1 2026 (no product sales; company remains pre-revenue).

**Business Highlights**

-   Initiated GMP manufacturing for AKTX-101 with WuXi Biologics/XDC to support IND and Phase 1 readiness targeted by mid-2027.
-   Company is prioritizing its PH1-based ADC platform and lead Trop-2 program (AKTX-101) while retaining optionality to expand the pipeline.
-   Scientific validation: An ASCO 2026 abstract was accepted demonstrating spliceosome modulator ADC synergy in KRAS‑mutated pancreatic cancer.
-   Operational model: Continued virtual manufacturing strategy relying on CDMOs for development, scale-up and GMP clinical supply.

Original SEC Filing: Akari Therapeutics Plc \[ AKTX \] - 10-Q - May. 19, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [AKTX.US](https://longbridge.com/en/quote/AKTX.US.md)
- [02269.HK](https://longbridge.com/en/quote/02269.HK.md)
- [02268.HK](https://longbridge.com/en/quote/02268.HK.md)
- [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md)

## Related News & Research

- [Akari Therapeutics Delays Quarterly SEC Filing](https://longbridge.com/en/news/286828350.md)
- [Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase | AKTX Stock News](https://longbridge.com/en/news/286776452.md)
- [Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer | SLXN Stock News](https://longbridge.com/en/news/286425411.md)
- [Sutro Biopharma: Buy Rating on Strong ADC Execution, Cash Runway Into 2028, and Multiple 2026 Catalysts](https://longbridge.com/en/news/286599325.md)
- [Orion Pharma to reveal initial results from Phase 1/2 TEADES study of ODM-212 at 2026 ASCO® Meeting.](https://longbridge.com/en/news/287177935.md)